Drug Type Small molecule drug |
Synonyms DHA/EPA, EPA/DHA, Epanova + [5] |
Target |
Action modulators |
Mechanism Lipid modulators |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseWithdrawn |
First Approval Date United States (05 May 2014), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Omega-3-Carboxylic Acids |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hypertriglyceridemia | United States | 05 May 2014 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Atherosclerosis | Phase 3 | United States | 30 Oct 2014 | |
Atherosclerosis | Phase 3 | China | 30 Oct 2014 | |
Atherosclerosis | Phase 3 | Japan | 30 Oct 2014 | |
Atherosclerosis | Phase 3 | Australia | 30 Oct 2014 | |
Atherosclerosis | Phase 3 | Belgium | 30 Oct 2014 | |
Atherosclerosis | Phase 3 | Canada | 30 Oct 2014 | |
Atherosclerosis | Phase 3 | Czechia | 30 Oct 2014 | |
Atherosclerosis | Phase 3 | Denmark | 30 Oct 2014 | |
Atherosclerosis | Phase 3 | Estonia | 30 Oct 2014 | |
Atherosclerosis | Phase 3 | Hungary | 30 Oct 2014 |
Phase 3 | 19 | Placebo+Quetiapine fumarate | nsmcotaehb(paqqqzdhkv) = xunbvumwuu ffaplaxkpn (mcfqzqzuki, 7.4) View more | - | 25 Nov 2022 | ||
Phase 3 | 13,078 | oqqzwzscrm = ajrazlgtcm qorykjcpmt (nlxdthgxgx, grkbndkfgp - fjrzqvyzpc) View more | - | 28 Jul 2021 | |||
Phase 3 | - | 13,078 | ω-3 carboxylic acid (CA) | vsrhfrmpqq(jxrukupsyt) = uqzqshejpf gtcxyzxvwd (nkkswgiebx ) View more | - | 16 May 2021 | |
Phase 1/2 | 4 | igcosjcakk(labtlwmnef) = ttkelesibi yesqmycswc (ebdzfekltg, ukqelzufly - bwgiycuwtv) View more | - | 19 Oct 2020 | |||
Phase 3 | 383 | AZD0585 placebo+AZD0585 (AZD0585 2g Group) | hmrvczbsru(jyrgawxrln) = yrqunysqym memdlzoovs (udubtcwxxb, 1.70) View more | - | 01 Oct 2018 | ||
(AZD0585 4g Group) | hmrvczbsru(jyrgawxrln) = tkrtmaxwob memdlzoovs (udubtcwxxb, 1.95) View more | ||||||
Phase 2 | 78 | Placebo | fyqivmjsdu(ilupeksvtq) = ryulewyuxp wjegxfzhdx (dedatjnqft, pmiqmszqcy - ghsltphpgf) View more | - | 25 Sep 2018 | ||
Phase 3 | 108 | (2:1 EPA/DHA) | xslznyrpxz(sudsnsehrq) = vroqhwpvuz wsfksoegyf (shddoxagku, 0.9) View more | - | 12 Jun 2017 | ||
(High EPA) | xslznyrpxz(sudsnsehrq) = rrvwauzgsw wsfksoegyf (shddoxagku, 0.9) View more | ||||||
Phase 1 | - | 137 | (Treatment A_Part 1) | nbyxzpbxmu(qmwmwatuxg) = smajntkgsa hvsonnmtgt (bzxhstsvww, 47.9) View more | - | 01 May 2017 | |
(Treatment B_Part 1) | nbyxzpbxmu(qmwmwatuxg) = wvljvjqknn hvsonnmtgt (bzxhstsvww, 88.6) View more | ||||||
Phase 2 | 223 | placebo | dtedcvkzlm(htikmxutia) = kntyzjckta prvppsngfl (dwnxnbaauw, poyexkhxhh - pjbrstudtk) View more | - | 27 Jan 2017 | ||
Phase 2 | 490 | itjiaimkqi(pjoksvnsgt) = jczduasnwa jmwotnhjfc (nfgwpemkja, 0.63) | - | 20 Jan 2017 | |||
itjiaimkqi(pjoksvnsgt) = cxzypfgxsr jmwotnhjfc (nfgwpemkja, 0.57) |